secwatch.observer — SEC 8-K summary
======================================

Issuer:     4D Molecular Therapeutics, Inc. (FDMT)
CIK:        0001650648
Form:       8-K
Filed at:   2024-06-07T23:59:59+00:00
Accession:  0001193125-24-157521
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

4D Molecular Therapeutics enters $250M ATM equity distribution agreement with Leerink Partners
--------------------------------------------------------------------------------

- Company enters Sales Agreement to sell up to $250M common stock via at-the-market offering through Leerink Partners.
- Agent compensation up to 3.0% of gross proceeds; sales made on Nasdaq via Rule 415(a)(4).
- Offering registered under existing S-3 filed Feb 2024; prospectus supplement filed June 7, 2024.
- No minimum sales obligation; company may terminate at any time upon prior notice.
- Proceeds for general corporate purposes; no escrow arrangement.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1650648/000119312524157521/0001193125-24-157521-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1650648/000119312524157521/d835355d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-157521

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer